Approval · Notice of Compliance 17650 · 2016
RAN-CLOPIDOGREL: Notice of Compliance 17650
Issued January 8, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 17650
- Date
- January 8, 2016
- Company
- Ranbaxy Pharmaceuticals Canada Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Additional product name
- Canadian reference product
- PLAVIX (Sanofi-Aventis Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RAN-CLOPIDOGREL | 02379813 | Marketed |
Medicinal ingredients
- CLOPIDOGREL 75 MG per TAB